About Palbociclib API
Therapeutic CategoryAnti-Cancer/ Oncology-pt
CAS Number
571190-30-2
API Technology
Synthetic
Dose Form
Capsule/ Tablet, Oral Solids
Dr Reddy's Development Status
Available
Available Regulatory Filing
Brazil DMF, USDMF, Singapore DMF
Mechanism of Action
It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
Indication
IBRANCE is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
- An aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or
- Fulvestrant in women with disease progression following endocrine therapy.
Related APIs
Enzalutamide-pt
Anti-Cancer/ Oncology-pt
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!